SV Health Investors is a healthcare fund manager with approximately $2.7bn in assets under management and a transatlantic presence spanning biotechnology, dementia, and healthcare technology.
Portfolio
2
companies
AUM
£2.7B
under management
EyeBio
EyeBio develops a pipeline of novel therapies for retinal and eye diseases.
NRG Therapeutics
NRG Therapeutics develops mitochondrial-targeted treatments for neurodegenerative conditions.
The financing round was led by SV Health Investors and will fund initial human trials for the company lead candidate in ALS and Parkinson's.
"Developing new drugs to treat neurological diseases is very challenging, but is receiving increased interest given the high unmet medical need and growing prevalence in ageing populations."
Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joined the financing round to support accelerated development of the company pipeline.
"We look forward to partnering with David Guyer and the world-class team at EyeBio to contribute to building a great company together"
